Longevity for Investors with Dr. Greg Bailey and Jess Larsen

Karl Pfleger, founder of AgingBiotech.info and a former Google researcher, dives deep into the rapidly evolving longevity biotech landscape. He discusses the lucrative opportunities in aging-related investments, highlighting how targeting aging could revolutionize health care. Pfleger stresses the importance of understanding mechanisms of action and shares his investment strategies. He also emphasizes the promise of senolytics, or senescent cell clearance, as a leading frontier. For aspiring investors, he recommends diving into conferences and varied resources for informed decisions.

The field of aging research is undergoing a revolution, and the Buck Institute is at the forefront of this transformative movement. In this captivating interview, Dr. Eric Verdin shares insights into the groundbreaking discoveries that are redefining our understanding of the aging process. From senescence and epigenetics to NAD metabolism and ketones, learn about the cutting-edge science that is paving the way for a future where age-related diseases are a thing of the past. Join us as we explore the exciting possibilities of the longevity revolution.

Lucio Iannone, Head of Health Venture Investments at Leaps by Bayer, is a seasoned biotech investor with a PhD from Imperial College. He discusses how Leaps is revolutionizing biotech investing with significant early checks and strategic acquisitions like BlueRock. Lucio shares insights on key investment principles, including the importance of medical need and scientific credibility. He also contrasts the US and European biotech landscapes, offers advice for founders seeking VC support, and highlights the focus on longevity and preventative health in their strategies.

In this discussion, venture investor Alex Colville, co-founder of age1, shares his journey from an early interest in longevity to deploying over $100 million into biotech startups. He emphasizes the significance of founder-market fit and the unexpected scalability of small investments. The conversation turns to the potential of the first longevity-approved drug, which could generate up to $200 billion annually. Alex also explores the exciting world of synthetic embryos and the bold risks necessary for early-stage investments.

In this insightful podcast episode, Dr. Jeff Karp shares powerful strategies to tap into your brain's neuroplasticity and rewire it for success. Discover how small changes in your daily life can lead to significant improvements in creativity, problem-solving, and overall well-being. Learn to intercept routine patterns and algorithms that limit your potential, and embrace a mindset of continuous learning and growth. Dr. Karp's new book, called LIT: Life Ignition Tools and his research at Harvard Medical School and MIT provides a scientific foundation for these life-changing techniques.

The Buck Institute, a pioneer in aging research, is uncovering how ketones impact healthspan. Dr. Brianna Stubbs, a world-champion athlete turned researcher, shares insights on how these molecules are more than just an energy source. They act as potent signaling molecules, influencing key aging pathways. Learn about the institute's groundbreaking work and how ketone drinks might help us live better, longer.

Join Dr. Greg Bailey, a medical doctor turned biotech entrepreneur, as he shares his journey from emergency medicine to building successful companies like Juvenessence. He discusses the booming market for longevity drugs, emphasizing the need for strong management and strategic investing. Greg offers insights on evaluating biotech teams, the importance of fitness and foundational health habits, and even the role of diet in longevity. Plus, he shares personal success stories, practical advice for new investors, and the potential impact of longevity on society.

Raising money for longevity research can be a daunting task, especially for founders without a traditional biotech background. Akshay Sangahvi shares his experiences and insights on overcoming these challenges and securing funding for Yuvan Research.